{
    "clinical_study": {
        "@rank": "57107", 
        "arm_group": {
            "arm_group_label": "icotinib plus gemcitabine", 
            "arm_group_type": "Experimental", 
            "description": "Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.\nGemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
        }, 
        "brief_summary": {
            "textblock": "Research Hypothesis: icotinib administered  in combination with gemcitabine has an\n      acceptable safety profile in subjects with locally advanced, unresectable or metastatic\n      pancreatic adenocarcinoma.The primary objective is to determine the safety profile of\n      icotinib in combination with gemcitabine in subjects with locally advanced, unresectable or\n      metastatic pancreatic adenocarcinoma."
        }, 
        "brief_title": "Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Locally advanced, unresectable or metastatic pancreatic cancer by histologic or\n             cytologic confirmation without previous chemotherapy or target therapy.\n\n          -  ECOG Performance Status of 0 to 1.\n\n          -  Adequate organ function as defined by study-specified laboratory tests.\n\n          -  Signed informed consent form.\n\n          -  Willing and able to comply with study procedures.\n\n        Exclusion Criteria:\n\n          -  Previous chemotherapy or target therapy.\n\n          -  Currently have or have history of certain study-specified heart, liver, kidney, lung,\n             neurological, immune or other medical conditions.\n\n          -  Systemically active steroids.\n\n          -  Another investigational product within 28 days prior to receiving study drug.\n\n          -  Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring\n             within 28 days prior to receiving study drug.\n\n          -  Infection with HIV, hepatitis B or C at screening.\n\n          -  Pregnant or lactating.\n\n          -  Conditions, including alcohol or drug dependence, or intercurrent illness that would\n             affect the patient's ability to comply with study visits and procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024633", 
            "org_study_id": "BD-IC-IV48"
        }, 
        "intervention": [
            {
                "arm_group_label": "icotinib plus gemcitabine", 
                "description": "Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.", 
                "intervention_name": "icotinib", 
                "intervention_type": "Drug", 
                "other_name": "Commana"
            }, 
            {
                "arm_group_label": "icotinib plus gemcitabine", 
                "description": "Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 26, 2013", 
        "number_of_arms": "1", 
        "official_title": "Phase I, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Icotinib Combined With Gemcitabine as First-line Treatment in Locally Advanced, Unresectable or Metastatic Pancreatic Cancer", 
        "overall_official": {
            "affiliation": "Second Affiliated Hospital of Zhejiang Univercity School of Medcine", 
            "last_name": "Tingbo Liang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The number of patients who suffer adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024633"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumor response assessed by RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}